RESUMO
The perioperative morbidity of local radical transurethral resection performed in 103 patients with muscle-invasive bladder cancer (T2-T3a) was 20%, their mortality 1%. The three- and five-year survivals were 54% and 36%, respectively. Within 5 years after transurethral resection of primary tumours relapses were encountered in 46%, progression in 33% of the cases. The cause of death was tumour in 29% of the patients, and some other disease in 35%. The full thickness transurethral resection combined with adjuvant treatment may be an alternative to cystectomy in selected cases of T2-T3a bladder cancer.
Assuntos
Neoplasias da Bexiga Urinária/cirurgia , Idoso , Terapia Combinada , Feminino , Seguimentos , Humanos , Masculino , Músculos/patologia , Invasividade Neoplásica , Recidiva Local de Neoplasia/epidemiologia , Estadiamento de Neoplasias , Procedimentos Cirúrgicos Operatórios/métodos , Taxa de Sobrevida , Uretra , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/mortalidade , Neoplasias da Bexiga Urinária/patologia , Neoplasias da Bexiga Urinária/radioterapiaRESUMO
A total of 126 patients, whose superficial bladder tumours (Ta-Tl) had been removed by TUR, were subjected to local BCG therapy. Marked by frequent though mild side effects, they presented a significantly lower rate of tumour recurrence than the control group under exclusive TUR treatment. During a follow-up period of 3 years, 74% of the patients proved recurrence-free. BCG and Adriamycin were found largely similar in degree of effectiveness.
